depression diagnosis

From 0 to 1 Is Difficult in European market—But We Will Never Quit   The journey from 0 to 1 is always the hardest. It’s the phase where doubt is loudest, resistance is strongest, and the path forward seems uncertain. But does that mean we quit now? The answer is never.    We stand at the heart of a critical mission: impacting 300 million depression patients by transforming mental healthcare. Pioneering a new era in mental health is not easy—there will always be objection, skepticism, and challenges. But those voices will never dismiss the power of our technology or the urgency of our cause.    Breaking the Barriers in Mental Health  For too long, depression diagnosis has relied on subjective assessments, leaving room for error, stigma, and delayed treatment. We are changing that. By bringing objective, data-driven diagnosis to mental health, we are shifting the paradigm—giving patients and professionals the tools they need to fight depression with precision and confidence.    The Movement Is Growing  Every day, more doctors, researchers, and patients are joining us in this fight. They see what we see: a future where depression is not just managed but understood, diagnosed, and treated with unprecedented accuracy. Their belief fuels our determination.    No Fear—Only Courage  We have no fear of the challenges ahead. Instead, we fight more bravely—because every obstacle we overcome brings us closer to a world where mental health is no longer shrouded in uncertainty.    This is not just a mission; it’s a revolution. And revolutions are not built by those who quit at the first sign of difficulty. They are built by those who persist, innovate, and refuse to back down.    We are here. We are fighting. And we will never stop. 

Circular RNA Biomarker Based Approach to Depression Diagnosis    Today we share a commonly asked question from our clients and our answer.

Circular RNA Biomarker Based Approach to Depression Diagnosis    Today we share a commonly asked question from our clients and our answer.

We are thrilled to announce our successful first participation in EuroMedLab Brussels 2025! Our exhibition booth attracted strong interest from laboratories across Europe, with valuable inquiries and potential orders received from Belgium, Germany, Italy, Spain, Portugal, Czech Republic, Switzerland, Finland,etc   Specializing in depression diagnosis, we offer Circular RNA RT PCR Detection Kit to enhance your laboratory testing capabilities. Our team is committed to supporting researchers and clinicians in developing more accurate diagnostic tools- particularly for mental health conditions like depression.     This exhibition marks just the beginning of our European journey. We look forward to building lasting partnerships with laboratories worldwide to advance precision diagnostics together.     Contact us today to explore how our solutions can benefit your work.   

Today's featured article:“The role of ncRNAs in depression” Xinchi Luan , Han Xing, Feifei Guo, Weiyi Liu, Yang Jiao, Zhenyu Liu, Xuezhe Wang, Shengli Gao   Hence, we methodically outlined the findings of published researches on ncRNAs and depression, focusing on microRNAs. Above all, this review aims to improve our understanding of ncRNAs and provide new insights of the diagnosis and treatment of depression.

Today's featured article: “Intranasal Delivery of circATF7IP siRNA via Lipid Nanoparticles Alleviates LPS-induced Depressive-Like Behaviors” by Minzi Ju, Zhongkun Zhang, Feng Gao, Gang Chen, Sibo Zhao, Dan Wang, Huijuan Wang , Yanpeng Jia, Ling Shen, Yonggui Yuan, Honghong Yao   These results indicate that the level of circATF7IP positively correlates with MDD pathogenesis, and SALNP delivery of si-circATF7IP via intranasal administration is an effective strategy to ameliorate LPS-induced depressive-like behaviors. Keywords: CircRNA; depression; lipid nanoparticle; neuroinflammation; oligonucleotide.